- |||||||||| Trial completion, Trial completion date: Velcade (Bortezomib) Consolidation After Transplant (clinicaltrials.gov) - Mar 8, 2018
P3, N=256, Completed, Active, not recruiting --> Completed | N=50 --> 10 Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
Trial completion, Trial completion date: Collection of Transplant Stem Cells for Plasma Cell Myeloma (clinicaltrials.gov) - Mar 7, 2018 P2, N=49, Completed, Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jan 2018
- |||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation (clinicaltrials.gov) - Mar 7, 2018
P=N/A, N=43, Terminated, Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jan 2018 N=300 --> 43 | Trial completion date: Dec 2019 --> Feb 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2018; FDA released requirement to complete study
- |||||||||| Clinical data, Trial completion date, HEOR: HAMLET: 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece (clinicaltrials.gov) - Mar 7, 2018
P=N/A, N=72, Active, not recruiting, N=300 --> 43 | Trial completion date: Dec 2019 --> Feb 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2018; FDA released requirement to complete study Trial completion date: Jan 2018 --> Mar 2018
- |||||||||| gandotinib (LY 2784544) / Eli Lilly
Trial completion date: A Study in Myeloproliferative Disorders (clinicaltrials.gov) - Mar 6, 2018 P1, N=80, Active, not recruiting, Trial completion date: Jan 2018 --> Mar 2018 Trial completion date: Aug 2018 --> Dec 2019
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: FEISTY: Fibrinogen Early In Severe Trauma studY (clinicaltrials.gov) - Mar 5, 2018
P2, N=100, Completed, Trial completion date: Aug 2018 --> Dec 2019 Recruiting --> Completed | Trial completion date: Jun 2018 --> Feb 2018 | Trial primary completion date: Dec 2017 --> Jan 2018
- |||||||||| Trial completion date: Control of Major Bleeding After Trauma Study (clinicaltrials.gov) - Mar 3, 2018
P2, N=144, Terminated, Trial completion date: Feb 2018 --> Mar 2018 Trial completion date: Apr 2018 --> Apr 2017
- |||||||||| Trial completion, Trial primary completion date: Comprehensive Frailty Assessment (clinicaltrials.gov) - Feb 28, 2018
P=N/A, N=111, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Aug 2017
- |||||||||| Farydak (panobinostat) / Secura Bio
Enrollment change, Trial completion date, Trial initiation date, Trial termination, Trial primary completion date: PANORAMA4: A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov) - Feb 23, 2018 P2, N=6, Terminated, Trial primary completion date: Dec 2018 --> Jul 2017 | Initiation date: Jul 2014 --> Aug 2014 N=112 --> 6 | Recruiting --> Terminated | Trial primary completion date: Feb 2021 --> May 2017 | Trial completion date: Feb 2021 --> May 2017 | Initiation date: Jun 2016 --> Jun 2016; A study was terminated due to low enrollment.
- |||||||||| Epogen (epoetin alfa) / Amgen
Trial completion, Enrollment change, Trial initiation date, HEOR: Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma (clinicaltrials.gov) - Feb 23, 2018 P=N/A, N=31, Completed, N=112 --> 6 | Recruiting --> Terminated | Trial primary completion date: Feb 2021 --> May 2017 | Trial completion date: Feb 2021 --> May 2017 | Initiation date: Jun 2016 --> Jun 2016; A study was terminated due to low enrollment. Active, not recruiting --> Completed | N=50 --> 31 | Initiation date: Mar 2005 --> Sep 2003
- |||||||||| Biostate (factor VIII/von Willebrand factor) / CSL Behring
Trial completion: Study of Voncento® in Subjects With Von Willebrand Disease (clinicaltrials.gov) - Feb 22, 2018 P4, N=26, Completed, Active, not recruiting --> Completed | N=50 --> 31 | Initiation date: Mar 2005 --> Sep 2003 Recruiting --> Completed
- |||||||||| dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial completion date, Trial primary completion date: Lenalidomide (Revlimid (clinicaltrials.gov) - Feb 19, 2018 P2, N=67, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Nov 2017 --> Nov 2017 | Trial primary completion date: Nov 2017 --> Nov 2017 Trial primary completion date: Dec 2017 --> Dec 2018 | Trial completion date: Dec 2017 --> Dec 2018
- |||||||||| Kymriah (tisagenlecleucel-T) / Novartis
Trial completion, Trial completion date: CART-19 for Multiple Myeloma (clinicaltrials.gov) - Feb 13, 2018 P1, N=13, Completed, Trial primary completion date: Dec 2018 --> Feb 2018 | Trial completion date: Dec 2018 --> Feb 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jan 2018
- |||||||||| bortezomib / Generic mfg., bendamustine / Generic mfg.
Trial termination: Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma (clinicaltrials.gov) - Feb 7, 2018 P2, N=24, Terminated, Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jan 2018 Completed --> Terminated; PI left the institution before all data analysis was completed
- |||||||||| lenalidomide / Generic mfg.
Biomarker, Trial termination: Lenalidomide Maintenance Therapy for Multiple Myeloma (clinicaltrials.gov) - Feb 6, 2018 P2, N=11, Terminated, Trial primary completion date: Dec 2017 --> Dec 2018 | Initiation date: Feb 2016 --> Feb 2016 Completed --> Terminated; Original investigator left the NIH and the primary outcome was not reached
- |||||||||| Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Enrollment closed, Enrollment change, Trial primary completion date, Patient reported outcomes: ECHO: Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (clinicaltrials.gov) - Feb 5, 2018 P=N/A, N=1482, Active, not recruiting, Trial primary completion date: Sep 2018 --> Dec 2017 Recruiting --> Active, not recruiting | N=2000 --> 1482 | Trial primary completion date: Dec 2020 --> Jan 2018
- |||||||||| Trial primary completion date: Individualizing Hemophilia Prophylaxis Using Thromboelastography (clinicaltrials.gov) - Jan 11, 2018
P=N/A, N=60, Recruiting, Active, not recruiting --> Completed | N=20 --> 11 | Trial primary completion date: Oct 2017 --> Jan 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- |||||||||| Phase classification, Trial termination, Trial primary completion date: Honey in Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Jan 9, 2018
P=N/A, N=30, Terminated, Trial primary completion date: Dec 2017 --> Dec 2018 Phase classification: P2 --> P=N/A | Suspended --> Terminated | Trial primary completion date: Jan 2017 --> Dec 2017; problem with the candidate (investigator)
|